Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Xencor ( (XNCR) ) just unveiled an update.
Xencor, Inc., a biopharmaceutical developer of engineered protein therapeutics, has relied on collaborations with major pharma companies to advance candidates such as cytokine-Fc fusion proteins. Its business model emphasizes partnering for late-stage development and commercialization in key therapeutic areas.
On March 4, 2026, Xencor disclosed that Genentech, a unit of Roche, will terminate their collaboration and license agreement, effective September 4, 2026, after Roche had already removed the joint drug efbalropendekin alfa from its development pipeline in January 2025. Xencor had stopped cost-sharing in the first half of 2024 by opting out of co-development, leaving Genentech solely responsible for development activities, so the administrative termination largely formalizes a wind-down that was already reflected in operations and pipeline expectations.
The most recent analyst rating on (XNCR) stock is a Sell with a $10.50 price target. To see the full list of analyst forecasts on Xencor stock, see the XNCR Stock Forecast page.
Spark’s Take on XNCR Stock
According to Spark, TipRanks’ AI Analyst, XNCR is a Neutral.
The score is weighed down primarily by deteriorating fundamentals (reported $0 revenue in 2025, sustained large losses, and heavy cash burn) and bearish technicals (price below key moving averages with negative MACD). A relatively strong balance sheet and stated cash runway provide some support, but the royalty dispute adds incremental downside risk.
To see Spark’s full report on XNCR stock, click here.
More about Xencor
Xencor, Inc. is a biopharmaceutical company that develops engineered protein therapeutics, including antibody and cytokine-Fc fusion products, for the treatment of serious diseases. The company partners with larger drug makers to advance clinical development and commercialization of its pipeline candidates across global markets.
Average Trading Volume: 712,975
Technical Sentiment Signal: Strong Sell
Current Market Cap: $830.2M
See more data about XNCR stock on TipRanks’ Stock Analysis page.